ALNY

AI Memo

Alnylam

As of 2026-10-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

ALN-HTT02 Phase 1 data at EHDN • 2026-10-23

Base target: $230 / p=50% prob

Biggest risk

The TTR guidance reduction indicates that early second-line demand was less durable than previously expected. Further launch deceleration or disappointing Phase 1 data could outweigh strong historical growth. [#SEC-8K-2026-07-30]

Invalidation

Break below $165 or thesis failure.

What would change my mind?

Q2 TTR revenue reached $1.030 billion, up 89% year over year, and continued ATTR-CM diagnosis and treatment growth could support the launch despite the reset. The October ALN-HTT02 readout offers a separate, high-risk pipeline option. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-06

Base target

$230

p=50%

Bull target

$280

p=25%

Bear target

$165

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ATTR-CM launch-volume test after guidance cut
Q2 TTR revenue reached $1.030 billion, up 89% year over year, and continued ATTR-CM diagnosis and treatment growth could support the launch despite the reset.
The October ALN-HTT02 readout offers a separate, high-risk pipeline option.

BearKey bullets

ALN-HTT02 Phase 1 results may reveal safety, tolerability, or biological-activity limitations; clinical efficacy is not established.
[#SEC-8K-2026-07-30]
Commercial growth depends on continued ATTR-CM diagnosis, treatment initiation, and competitive execution; the packet lacks current channel-level launch data.

WatchKey bullets

ALN-HTT02 Phase 1 data at EHDN

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $230 (p=50%)

Target spread vs base: +22% / -28%

Scenario probabilities

Bull Target: $280 (p=25%)Base Target: $230 (p=50%)Bear Target: $165 (p=25%)

Commentary

The supplied recent-news items are mostly unrelated to Alnylam, so they do not establish positive company-specific news tone. The October 5 price anchor is not a verified post-release reaction measure. Social, options, short-interest, employee, and post-guidance analyst-revision data are unavailable; zero values in the sentiment fields denote unavailable measurements, not neutral observations. The structured prior is positive but has lower catalyst density than the earlier baseline, supporting cautious monitoring rather than an upgrade.

As of 2026-10-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ATTR-CM launch-volume test after guidance cut

Scenarios

Bull Target (Scenario probability)

$280 / p=25% prob

Base Target (Scenario probability)

$230 / p=50% prob

Bear Target (Scenario probability)

$165 / p=25% prob

Analysis 2026-10-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-23
ALN-HTT02 Phase 1 data at EHDN
Alnylam said initial Huntington's disease Phase 1 results would be presented at EHDN. The congress runs October 22–24, 2026; October 23 is a monitoring date, not a confirmed presentation slot. Safety and efficacy remain unestablished. [#8-K-2026-07-30] [#SEC-8K-2026-07-30] EHDN congress schedule
Prob 70.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

ATTR-CM launch-volume test after guidance cut
2026-11-15
Q2 2026 global product revenue was $1.172 billion, but Alnylam cut full-year TTR revenue guidance from $4.4–$4.7 billion to $4.2–$4.5 billion. Management attributed the reset partly to normalization of second-line volume after pent-up demand. Subsequent sales will test whether diagnosis and treatment growth offsets that normalization; the date is an estimated review window, not an announced reporting date. [#8-K-2026-07-30] [#SEC-8K-2026-07-30]
Prob 65% • Move -8% • Priced-in 65%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

ALN-HTT02 Phase 1 results may reveal safety, tolerability, or biological-activity limitations; clinical efficacy is not established. [#SEC-8K-2026-07-30]
Commercial growth depends on continued ATTR-CM diagnosis, treatment initiation, and competitive execution; the packet lacks current channel-level launch data.
Further normalization of second-line ATTR-CM volume could prompt another TTR revenue-guidance reduction. [#SEC-8K-2026-07-30]

Peers

Symbol	Summary
BBIO	Direct approved-product ATTR-CM competitor: BridgeBio markets oral ATTRUBY (acoramidis). Alnylam identifies its pill administration and lower U.S. list price as potential competitive pressures on AMVUTTRA. This is a product-market comparator, not an interchangeable company valuation. [#10-K-2026-02-12] Alnylam 10-K
IONS	Direct prospective ATTR-CM treatment comparator rather than a current approved ATTR-CM sales peer: Alnylam's 2025 10-K lists Ionis and AstraZeneca's WAINUA (eplontersen) among Phase 3 ATTR-CM candidates. Its future competitive effect depends on trial and regulatory outcomes. [#10-K-2026-02-12] Alnylam 10-K
PFE	Direct approved-product ATTR-CM competitor: Pfizer markets oral VYNDAQEL/VYNDAMAX (tafamidis). Alnylam's 2025 10-K says its pill administration and lower U.S. list price may pressure AMVUTTRA share and net revenue. This is an operating comparator, not a close whole-company valuation peer. [#10-K-2026-02-12] Alnylam 10-K
REGN	RNAi development partner, not a direct AMVUTTRA sales comparator. Regeneron's July 2026 filing describes an Alnylam collaboration covering eye, CNS, and selected liver targets; the target-nomination period ended in May 2026, but the filing does not say the broader collaboration ended. No economic exposure is quantified. [#REL-4a63e51e-aef6-4cda-8442-1d7a7a7c2813] Regeneron filing

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-06

Loading AI feed…

Symbol

Summary

BBIO

Direct approved-product ATTR-CM competitor: BridgeBio markets oral ATTRUBY (acoramidis). Alnylam identifies its pill administration and lower U.S. list price as potential competitive pressures on AMVUTTRA. This is a product-market comparator, not an interchangeable company valuation. [#10-K-2026-02-12] Alnylam 10-K

IONS

Direct prospective ATTR-CM treatment comparator rather than a current approved ATTR-CM sales peer: Alnylam's 2025 10-K lists Ionis and AstraZeneca's WAINUA (eplontersen) among Phase 3 ATTR-CM candidates. Its future competitive effect depends on trial and regulatory outcomes. [#10-K-2026-02-12] Alnylam 10-K

PFE

Direct approved-product ATTR-CM competitor: Pfizer markets oral VYNDAQEL/VYNDAMAX (tafamidis). Alnylam's 2025 10-K says its pill administration and lower U.S. list price may pressure AMVUTTRA share and net revenue. This is an operating comparator, not a close whole-company valuation peer. [#10-K-2026-02-12] Alnylam 10-K

REGN

RNAi development partner, not a direct AMVUTTRA sales comparator. Regeneron's July 2026 filing describes an Alnylam collaboration covering eye, CNS, and selected liver targets; the target-nomination period ended in May 2026, but the filing does not say the broader collaboration ended. No economic exposure is quantified. [#REL-4a63e51e-aef6-4cda-8442-1d7a7a7c2813] Regeneron filing